Medicare Payment Demo Would Put Often-Prescribed Cancer Drugs ‘Underwater’
Executive Summary
Community oncology practices and hospitals strongly object to CMS’ plan for testing different reimbursement formula Part B drugs, which is expected to particularly impact treatments for cancer, arthritis and eye disease.
You may also be interested in...
CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does
President-elect Trump’s selection for HHS secretary, Rep. Tom Price, R-Ga., has been an outspoken critic of the proposed Medicare Part B drug demonstration project.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.